CLINICAL QUESTION What is the best current disease-modifying therapy for relapsing-remitting multiple sclerosis? RESULTS The evidence shows that the most effective disease-modifying therapy for delaying short- to medium-term disability progression, prevention of relapses, reducing the area and activity of lesions on magnetic resonance imaging, with the least side effects, is high-dose, high-f...

Introduction. Ocrelizumab is a recombinant humanized monoclonal antibody that selectively depletes CD20-expressing B cells, which approved for the treatment of relapsing and primary progressive multiple sclerosis (MS). It extremely rarely associated with late-onset neutropenia (LON), as an adverse event. Case outline. We describe case, from Treatment Registry Clinic Neurology, University Clinic...

PURPOSE To evaluate the use of magnetization transfer and the apparent enhancement of lesions on contrast-enhanced MR images in patients with multiple sclerosis. METHODS Contrast-enhanced T1-weighted spin-echo MR images obtained in 20 patients with relapsing-remitting multiple sclerosis, with and without magnetization transfer, were evaluated to determine the number of enhancing plaques. Comp...

OBJECTIVE To prospectively characterise treatment persistence and predictors of treatment discontinuation in an Australian relapsing-remitting multiple sclerosis (RRMS) population. METHODS Tertiary MS treatment centres participating in the MSBase registry prospectively assessed treatment utilisation, persistence, predictors of treatment discontinuation and switch rates. Multivariable survival...